For instance, multiple agents that inhibit PAPR1 activity have been approved by FDA and currently applied in non-cancer disease treatments where they demonstrated decent efficacy (Garber, 2013; Harrison, 2013); some antidiabetic chemicals like metformin can suppress the production of inflammatory cytokines generated by senescent cells and inhibit their secretory phenotype by interfering with IKK/NF-κB activation (Moiseeva et al., 2013). Here, NFKB1 is linked to cancer.